拓扑替康作为二线化疗药物在卵巢癌化疗中的药物敏感性实验

Chemosensitivity Testing of Topotecan as Second-Line Agent in Chemotherapy of Ovarian Cancer

背景与目的:晚期卵巢癌的治疗通常采用肿瘤细胞减灭术辅以化学治疗,常用的一线化疗方案为含顺铂的联合化疗,但绝大多数晚期卵巢癌容易复发,并产生耐药,本研究通过药物敏感性实验评价拓扑替康在复发性和对顺铂耐药的卵巢癌患者中应用的临床价值。方法:采用三磷酸腺苷生物发光法对41例新鲜卵巢癌组织标本(其中9例为复发癌组织标本)进行药敏实验,药物采用顺铂和拓扑替康,分别配制成1倍血浆峰值浓度。结果:41例卵巢癌组织标本中,对拓扑替康敏感的比率(80.5%)高于顺铂(51.2%),在21例对顺铂耐药的卵巢癌组织标本中有18例对拓扑替康敏感。结论:拓扑替康可以作为一种较好的二线化疗药物用于卵巢癌患者的化疗,特别是在对顺铂耐药的情况下。

BACKGROUND &OBJECTIVE: The therapeutic principle of ovarian can ce r was cytoreductive surgery assisting with chemotherapy. At present, cisplatin- based chemotherapy is the primary way for treatment of ovarian cancer. But most patients with advanced ovarian cancer were easy to recurrent and then become res istance to cisplatin. This study was designed to evaluate the clinical applicati on of topotecan in recurrent ovarian cancer and ovarian cancer resistant to cisp latin. METHODS: An adenosine triphosphate chemosensitivity assay (ATP-CSA) was used to determine the drug sensitivity of 41 tissue specimens of fresh ovarian c ancer. Cisplatin and topotecan were used as chemotherapeutic agents [1×Peak Pla sma Concentration (PPC)], and then the results were analyzed. RESULTS: (1) In 41 specimens, the results showed that topotecan was more sensitive (80.5%) than c isplatin (51.2%). (2) In 20 cisplatin-resistance specimens, there were 18 spec imens sensitive to topotecan. CONCLUSIONS: Topotecan could be a kind of better s econd line drug in treating ovarian cancer, particularly when the patient was re sistant to cisplatin.